Literature DB >> 18711028

Trastuzumab in inflammatory breast cancer.

R S Mehta, T Schubbert, K Kong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18711028      PMCID： PMC2735067          DOI： 10.1093/annonc/mdn555

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Authors:  Roman Rouzier; Charles M Perou; W Fraser Symmans; Nuhad Ibrahim; Massimo Cristofanilli; Keith Anderson; Kenneth R Hess; James Stec; Mark Ayers; Peter Wagner; Paolo Morandi; Chang Fan; Islam Rabiul; Jeffrey S Ross; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.

Authors:  Dang M Nguyen; Kathy Sam; Anna Tsimelzon; Xiaoxian Li; Helen Wong; Syed Mohsin; Gary M Clark; Susan G Hilsenbeck; Richard M Elledge; D Craig Allred; Peter O'Connell; Jenny C Chang
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

3.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Authors:  Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-02-13       Impact factor: 44.544

4.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Trends for inflammatory breast cancer: is survival improving?

Authors:  Ana M Gonzalez-Angulo; Bryan T Hennessy; Kristine Broglio; Funda Meric-Bernstam; Massimo Cristofanilli; Sharon H Giordano; Thomas A Buchholz; Aysegul Sahin; S Eva Singletary; Aman U Buzdar; Gabriel N Hortobágyi
Journal:  Oncologist       Date:  2007-08
  5 in total
  4 in total

1.  Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.

Authors:  Albert E Cerussi; Vaya W Tanamai; David Hsiang; John Butler; Rita S Mehta; Bruce J Tromberg
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2011-11-28       Impact factor: 4.226

2.  Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.

Authors:  Zsolt Horváth; László Torday; Erika Hitre; Erna Ganofszky; Eva Juhos; Ferenc Czeglédi; László Urbán; Csaba Polgár; István Láng; Sándor Eckhardt; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2010-12-14       Impact factor: 3.201

3.  Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.

Authors:  Leona Bessonova; Thomas H Taylor; Rita S Mehta; Jason A Zell; Hoda Anton-Culver
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-01-07       Impact factor: 4.254

4.  Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.

Authors:  Jason A Zell; Walter Y Tsang; Thomas H Taylor; Rita S Mehta; Hoda Anton-Culver
Journal:  Breast Cancer Res       Date:  2009-02-19       Impact factor: 6.466
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.